

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.7	103.2	(49.4-189.9)	Male	3	6.4	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	43	37.6	114.3	(82.7-154.0)	Female	5	4.3	117.1	(37.7-273.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.3	nc	(nc-nc)	Male	7	5.1	137.2	(55.0-282.6)
<u>Colon / Rectum</u>					Female	4	1.9	nc	(nc-nc)
Male	12	10.8	110.8	(57.2-193.6)	<u>Ovary</u>				
Female	3	8.4	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.7	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	2.9	174.6	(56.3-407.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	42	33.9	124.1	(89.4-167.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	5	5.9	85.0	(27.4-198.5)	Female	1	1.1	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.3	81.8	(29.9-178.1)
Male	2	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.4	nc	(nc-nc)	Female	10	8.5	117.3	(56.1-215.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.7	nc	(nc-nc)	Male	127	132.3	96.0	(80.0-114.2)
Female	1	1.0	nc	(nc-nc)	Female	138	119.1	115.9	(97.4-136.9)
<u>Lung and Bronchus</u>									
Male	16	17.6	90.7	(51.8-147.3)					
Female	27	15.8	171.0	(112.6-248.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	22.1	63.2	(34.5-106.1)	Male	5	14.1	35.6	(11.5-83.0)
Female	11	8.2	133.6	(66.6-239.1)	Female	8	10.9	73.4	(31.6-144.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	6	3.5	171.9	(62.8-374.2)	Female	3	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	12.7	78.9	(37.8-145.1)
Female	65	85.7	75.8	(58.5-96.7)	Female	11	11.3	97.2	(48.4-173.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	13	10.2	127.4	(67.8-217.9)
<u>Colon / Rectum</u>					Female	4	4.7	nc	(nc-nc)
Male	27	24.0	112.7	(74.2-164.0)	<u>Ovary</u>				
Female	23	23.8	96.5	(61.2-144.8)	Female	9	7.5	120.6	(55.0-228.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	5.6	233.9	(124.4-399.9)	Male	8	7.8	102.8	(44.3-202.6)
Female	2	1.6	nc	(nc-nc)	Female	7	8.4	83.6	(33.5-172.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	43	64.7	66.5	(48.1-89.6)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.3	nc	(nc-nc)
Male	15	12.0	124.6	(69.7-205.6)	Female	4	3.3	nc	(nc-nc)
Female	7	7.0	100.5	(40.3-207.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
<u>Leukemia</u>					Female	9	15.5	58.2	(26.6-110.6)
Male	11	9.0	122.1	(60.9-218.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.7	150.3	(72.0-276.5)	Female	21	19.2	109.2	(67.6-167.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	7.5	173.0	(92.0-295.9)	Male	265	280.4	94.5	(83.5-106.6)
Female	4	2.7	nc	(nc-nc)	Female	286	295.5	96.8	(85.9-108.7)
<u>Lung and Bronchus</u>									
Male	53	38.4	138.0	(103.3-180.5)					
Female	53	42.0	126.1	(94.4-164.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.6	nc	(nc-nc)	Male	7	5.7	123.5	(49.5-254.5)
Female	1	2.6	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.1	156.6	(67.4-308.6)
Female	32	35.1	91.2	(62.4-128.8)	Female	1	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.7	nc	(nc-nc)
Male	7	9.7	72.3	(29.0-149.0)	<u>Ovary</u>				
Female	7	8.0	87.5	(35.1-180.4)	Female	0	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.3	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	35	29.3	119.5	(83.2-166.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	5	5.2	95.6	(30.8-223.1)	Female	0	1.0	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.7	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	11	7.9	139.3	(69.4-249.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.1	nc	(nc-nc)	Male	105	116.4	90.2	(73.8-109.2)
Female	1	0.9	nc	(nc-nc)	Female	96	110.7	86.8	(70.3-105.9)
<u>Lung and Bronchus</u>									
Male	8	15.8	50.7	(21.8-100.0)					
Female	12	14.7	81.6	(42.1-142.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.7	77.6	(28.3-168.8)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.4	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	22	26.0	84.8	(53.1-128.3)
Female	0	0.2	nc	(nc-nc)	Female	22	24.7	88.9	(55.7-134.7)
<u>Lung and Bronchus</u>									
Male	9	3.4	261.2	(119.2-495.9)					
Female	4	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	38.3	107.1	(76.9-145.3)	Male	27	23.7	113.8	(75.0-165.6)
Female	23	14.8	155.6	(98.6-233.4)	Female	19	19.1	99.6	(60.0-155.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.8	nc	(nc-nc)	Male	7	7.8	89.3	(35.8-183.9)
Female	5	6.0	83.5	(26.9-194.8)	Female	3	6.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	25	21.3	117.2	(75.8-173.0)
Female	171	158.7	107.7	(92.2-125.1)	Female	24	20.3	118.4	(75.8-176.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.8	nc	(nc-nc)	Male	22	18.2	120.9	(75.8-183.1)
<u>Colon / Rectum</u>					Female	10	8.5	117.4	(56.2-215.9)
Male	41	40.3	101.7	(73.0-138.0)	<u>Ovary</u>				
Female	49	42.1	116.3	(86.0-153.7)	Female	20	13.7	146.1	(89.2-225.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	10.1	138.6	(75.7-232.5)	Male	24	13.8	174.4	(111.7-259.5)
Female	1	2.9	nc	(nc-nc)	Female	11	15.0	73.5	(36.7-131.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	134	128.3	104.5	(87.5-123.7)
Female	4	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	9.2	98.3	(44.9-186.7)
Male	22	21.1	104.2	(65.3-157.8)	Female	2	5.7	nc	(nc-nc)
Female	13	12.7	102.3	(54.4-174.9)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.9	nc	(nc-nc)
Male	8	5.9	136.1	(58.6-268.2)	<u>Thyroid</u>				
Female	3	1.8	nc	(nc-nc)	Male	12	8.8	136.8	(70.6-239.0)
<u>Leukemia</u>					Female	26	26.1	99.5	(65.0-145.8)
Male	24	14.9	160.6	(102.9-239.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	11.3	105.8	(54.6-184.8)	Female	27	36.3	74.4	(49.0-108.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	13.6	44.2	(16.1-96.2)	Male	561	497.0	112.9	(103.7-122.6)
Female	6	4.8	123.8	(45.2-269.4)	Female	575	534.9	107.5	(98.9-116.6)
<u>Lung and Bronchus</u>									
Male	88	68.7	128.1	(102.7-157.8)					
Female	101	78.0	129.5	(105.5-157.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	16.9	77.0	(41.0-131.7)
Female	0	0.2	nc	(nc-nc)	Female	11	18.5	59.5	(29.7-106.5)
<u>Lung and Bronchus</u>									
Male	1	2.3	nc	(nc-nc)					
Female	0	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.5	115.4	(69.5-180.3)	Male	9	11.1	81.3	(37.1-154.4)
Female	5	5.7	88.3	(28.5-206.2)	Female	9	8.7	103.6	(47.3-196.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	3.6	251.1	(114.6-476.7)	Male	4	3.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	9.9	60.4	(22.1-131.5)
Female	78	70.4	110.8	(87.5-138.2)	Female	7	8.3	84.6	(33.9-174.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	14	8.4	165.8	(90.6-278.3)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	14	18.8	74.3	(40.6-124.7)	<u>Ovary</u>				
Female	19	17.0	111.9	(67.3-174.7)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.3	nc	(nc-nc)	Male	3	6.0	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	59	52.0	113.5	(86.4-146.5)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.1	nc	(nc-nc)
Male	14	9.8	142.5	(77.8-239.1)	Female	2	2.3	nc	(nc-nc)
Female	5	5.4	91.9	(29.6-214.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.7	nc	(nc-nc)
Male	7	2.5	279.8	(112.1-576.5)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	7	4.8	145.5	(58.3-299.8)
<u>Leukemia</u>					Female	15	14.3	104.6	(58.5-172.5)
Male	11	7.2	153.8	(76.7-275.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	4.9	185.0	(84.4-351.2)	Female	15	15.3	98.2	(54.9-162.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.0	nc	(nc-nc)	Male	232	220.3	105.3	(92.2-119.8)
Female	0	1.9	nc	(nc-nc)	Female	243	228.7	106.3	(93.3-120.5)
<u>Lung and Bronchus</u>									
Male	32	29.1	109.9	(75.1-155.1)					
Female	36	30.8	117.0	(81.9-162.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.7	189.9	(76.1-391.4)
Female	18	30.3	59.4	(35.2-93.9)	Female	2	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	8	6.9	115.2	(49.6-227.0)	<u>Ovary</u>				
Female	7	7.6	92.1	(36.9-189.9)	Female	4	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	18	22.2	80.9	(47.9-127.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	8	2.3	347.8	(149.8-685.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.7	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.1	nc	(nc-nc)	Female	6	6.9	87.4	(31.9-190.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.5	nc	(nc-nc)	Male	83	85.7	96.8	(77.1-120.0)
Female	2	0.9	nc	(nc-nc)	Female	77	99.1	77.7	(61.3-97.1)
<u>Lung and Bronchus</u>									
Male	15	11.2	134.2	(75.1-221.4)					
Female	11	13.1	84.2	(42.0-150.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
Female	7	7.5	93.0	(37.2-191.6)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	7.6	131.9	(63.1-242.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	5	1.8	285.2	(91.9-665.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	28	28.8	97.4	(64.7-140.7)
Female	0	0.2	nc	(nc-nc)	Female	25	24.2	103.3	(66.8-152.5)
<u>Lung and Bronchus</u>									
Male	2	4.0	nc	(nc-nc)					
Female	4	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	7.8	167.4	(89.1-286.3)	Male	8	4.9	162.1	(69.8-319.4)
Female	6	3.8	159.8	(58.3-347.8)	Female	3	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	38	35.4	107.5	(76.1-147.5)	Female	4	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	6	8.4	71.3	(26.0-155.3)	<u>Ovary</u>				
Female	11	10.5	104.3	(52.0-186.7)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	31	23.1	134.4	(91.3-190.7)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.9	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	3	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.4	147.2	(63.4-290.1)
Male	3	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	5	8.1	61.9	(20.0-144.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.7	nc	(nc-nc)	Male	116	98.7	117.5	(97.1-140.9)
Female	1	1.2	nc	(nc-nc)	Female	126	125.5	100.4	(83.7-119.6)
<u>Lung and Bronchus</u>									
Male	17	13.4	126.8	(73.8-203.0)					
Female	23	19.0	121.1	(76.8-181.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	21.5	83.6	(49.5-132.2)	Male	9	13.5	66.4	(30.3-126.1)
Female	6	7.7	77.9	(28.4-169.5)	Female	7	10.2	68.7	(27.5-141.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.0	150.0	(54.8-326.5)	Male	4	4.4	nc	(nc-nc)
Female	6	3.2	187.5	(68.5-408.1)	Female	3	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	4	12.1	nc	(nc-nc)
Female	71	80.7	88.0	(68.7-111.0)	Female	12	10.6	113.1	(58.4-197.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	9	10.0	89.6	(40.9-170.1)
<u>Colon / Rectum</u>					Female	3	4.4	nc	(nc-nc)
Male	26	22.8	114.1	(74.5-167.2)	<u>Ovary</u>				
Female	27	22.6	119.3	(78.6-173.6)	Female	6	7.0	85.4	(31.2-185.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.5	nc	(nc-nc)	Male	9	7.7	116.5	(53.2-221.1)
Female	3	1.5	nc	(nc-nc)	Female	8	8.0	100.4	(43.2-197.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.5	326.3	(105.2-761.5)	Male	36	68.4	52.7	(36.9-72.9)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.2	nc	(nc-nc)
Male	7	11.7	59.6	(23.9-122.8)	Female	4	3.1	nc	(nc-nc)
Female	5	6.5	77.2	(24.9-180.1)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.7	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	14.3	nc	(nc-nc)
Male	6	8.6	70.1	(25.6-152.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.2	97.3	(35.5-211.7)	Female	20	18.2	109.9	(67.1-169.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.6	nc	(nc-nc)	Male	205	276.9	74.0	(64.2-84.9)
Female	5	2.5	200.2	(64.5-467.1)	Female	275	277.2	99.2	(87.8-111.7)
<u>Lung and Bronchus</u>									
Male	27	38.3	70.6	(46.5-102.7)					
Female	48	38.8	123.7	(91.2-164.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	11.1	62.8	(25.2-129.4)	Male	3	7.5	nc	(nc-nc)
Female	0	3.6	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
Female	38	48.0	79.1	(56.0-108.6)	Female	5	5.4	92.3	(29.7-215.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.6	nc	(nc-nc)	Male	6	6.0	99.6	(36.4-216.8)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	16	12.8	124.7	(71.2-202.5)	<u>Ovary</u>				
Female	10	11.1	90.4	(43.3-166.2)	Female	2	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.1	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	31	38.6	80.2	(54.5-113.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.8	nc	(nc-nc)
Male	4	6.9	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.4	358.0	(115.4-835.4)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	6	3.2	190.2	(69.5-414.0)
<u>Leukemia</u>					Female	8	9.1	88.0	(37.9-173.5)
Male	3	4.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	3.0	nc	(nc-nc)	Female	12	10.8	110.8	(57.2-193.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.4	nc	(nc-nc)	Male	122	153.5	79.5	(66.0-94.9)
Female	2	1.3	nc	(nc-nc)	Female	110	151.1	72.8	(59.8-87.7)
<u>Lung and Bronchus</u>									
Male	11	20.3	54.1	(27.0-96.9)					
Female	10	19.8	50.5	(24.2-92.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.5	70.8	(25.8-154.0)	Male	5	5.4	93.4	(30.1-218.0)
Female	3	2.8	nc	(nc-nc)	Female	11	3.9	285.4	(142.3-510.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.8	145.6	(58.3-300.0)
Female	39	33.0	118.2	(84.0-161.5)	Female	6	3.9	152.1	(55.5-331.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	3	9.1	nc	(nc-nc)	<u>Ovary</u>				
Female	6	8.0	74.9	(27.4-163.1)	Female	4	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	5	3.0	165.0	(53.2-385.1)
Female	1	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	29	26.6	108.8	(72.9-156.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.5	145.2	(62.5-286.1)
Male	2	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	5	7.7	65.3	(21.0-152.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.9	nc	(nc-nc)	Male	86	109.3	78.7	(62.9-97.2)
Female	1	1.0	nc	(nc-nc)	Female	121	107.2	112.8	(93.6-134.8)
<u>Lung and Bronchus</u>									
Male	10	15.3	65.3	(31.2-120.0)					
Female	14	15.1	92.8	(50.7-155.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.0	86.2	(31.5-187.6)	Male	2	4.2	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	27	30.1	89.7	(59.1-130.5)	Female	5	4.2	120.3	(38.8-280.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	6	3.1	196.7	(71.8-428.1)
<u>Colon / Rectum</u>					Female	0	1.7	nc	(nc-nc)
Male	5	7.1	70.4	(22.7-164.4)	<u>Ovary</u>				
Female	12	8.8	137.1	(70.7-239.4)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	21.6	88.1	(53.0-137.6)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.6	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.6	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.4	nc	(nc-nc)	Female	13	6.9	188.8	(100.4-322.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	66	86.7	76.1	(58.8-96.8)
Female	1	1.0	nc	(nc-nc)	Female	88	106.3	82.8	(66.4-102.0)
<u>Lung and Bronchus</u>									
Male	5	12.3	40.6	(13.1-94.7)					
Female	7	16.1	43.4	(17.4-89.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.7	90.8	(36.4-187.1)	Male	4	5.2	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	32	34.9	91.8	(62.8-129.5)	Female	6	4.3	139.9	(51.1-304.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	4.0	126.2	(40.7-294.5)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	13	8.9	146.6	(78.0-250.7)	<u>Ovary</u>				
Female	13	9.0	143.8	(76.5-245.9)	Female	3	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.0	nc	(nc-nc)	Male	8	2.8	283.7	(122.1-559.0)
Female	1	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	36	23.9	150.5	(105.4-208.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	8	4.6	172.8	(74.4-340.6)	Female	1	1.2	nc	(nc-nc)
Female	5	2.7	183.3	(59.1-427.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	12	6.3	190.8	(98.5-333.3)
Male	4	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.4	nc	(nc-nc)	Female	13	7.4	175.5	(93.4-300.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.8	nc	(nc-nc)	Male	131	102.7	127.5	(106.6-151.3)
Female	2	1.0	nc	(nc-nc)	Female	128	114.9	111.4	(92.9-132.5)
<u>Lung and Bronchus</u>									
Male	17	13.9	122.2	(71.2-195.7)					
Female	16	16.2	98.5	(56.3-159.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.0	75.1	(27.4-163.4)	Male	4	5.2	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	6	4.2	143.8	(52.5-313.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	41	34.5	118.8	(85.2-161.1)	Female	11	4.2	263.3	(131.3-471.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	3	8.8	nc	(nc-nc)	<u>Ovary</u>				
Female	11	8.6	127.4	(63.5-228.0)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	26	26.4	98.4	(64.3-144.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	8	4.7	171.5	(73.8-337.9)	Female	0	1.2	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	5	2.1	232.7	(75.0-543.0)
<u>Leukemia</u>					Female	7	6.3	111.1	(44.5-228.9)
Male	5	3.4	148.5	(47.9-346.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	5	7.7	64.6	(20.8-150.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	100	106.6	93.8	(76.3-114.1)
Female	0	1.0	nc	(nc-nc)	Female	122	113.1	107.9	(89.6-128.8)
<u>Lung and Bronchus</u>									
Male	14	14.5	96.8	(52.9-162.4)					
Female	12	15.7	76.3	(39.4-133.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.4	95.6	(41.2-188.4)	Male	2	5.1	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.5	177.1	(76.2-348.9)
Female	23	26.6	86.4	(54.7-129.6)	Female	2	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	4	8.5	nc	(nc-nc)	<u>Ovary</u>				
Female	3	7.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	20	25.7	77.7	(47.4-120.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	5	4.4	114.1	(36.8-266.2)	Female	1	1.0	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	0.6	801.5	(258.3-1870.3)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	5	6.0	82.7	(26.7-193.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.8	nc	(nc-nc)	Male	81	104.3	77.7	(61.7-96.6)
Female	0	0.8	nc	(nc-nc)	Female	63	89.8	70.2	(53.9-89.8)
<u>Lung and Bronchus</u>									
Male	9	15.2	59.2	(27.0-112.3)					
Female	8	13.0	61.6	(26.5-121.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	10.7	102.7	(51.2-183.8)
Female	0	0.1	nc	(nc-nc)	Female	9	11.0	81.9	(37.4-155.5)
<u>Lung and Bronchus</u>									
Male	0	1.4	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.5	112.2	(61.3-188.2)	Male	20	8.6	233.9	(142.8-361.2)
Female	7	5.2	134.4	(53.8-276.8)	Female	4	7.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.8	178.9	(57.7-417.6)	Male	2	2.8	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.7	104.5	(45.0-205.9)
Female	80	61.0	131.2	(104.0-163.3)	Female	10	7.4	134.3	(64.3-247.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.0	nc	(nc-nc)	Male	7	6.8	102.4	(41.0-210.9)
<u>Colon / Rectum</u>					Female	2	3.2	nc	(nc-nc)
Male	18	14.2	126.5	(74.9-200.0)	<u>Ovary</u>				
Female	18	15.1	119.1	(70.5-188.2)	Female	5	5.2	96.4	(31.1-225.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.5	142.6	(45.9-332.7)	Male	1	4.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	64	43.8	146.2	(112.6-186.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	4	7.9	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	5	4.8	105.1	(33.9-245.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	12	11.2	106.7	(55.1-186.4)
Male	6	5.5	109.1	(39.8-237.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.3	nc	(nc-nc)	Female	18	13.9	129.6	(76.8-204.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.9	nc	(nc-nc)	Male	188	174.4	107.8	(92.9-124.3)
Female	0	1.8	nc	(nc-nc)	Female	215	200.9	107.0	(93.2-122.3)
<u>Lung and Bronchus</u>									
Male	17	23.0	73.9	(43.0-118.4)					
Female	30	27.7	108.4	(73.1-154.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.5	115.9	(57.8-207.5)	Male	7	6.6	105.5	(42.3-217.5)
Female	3	3.1	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
Female	31	43.0	72.0	(48.9-102.2)	Female	4	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	9	5.5	162.9	(74.3-309.2)
<u>Colon / Rectum</u>					Female	2	2.1	nc	(nc-nc)
Male	13	11.1	116.6	(62.0-199.4)	<u>Ovary</u>				
Female	11	9.2	119.6	(59.6-213.9)	Female	3	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.8	nc	(nc-nc)	Male	5	3.6	137.4	(44.3-320.7)
Female	1	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	31	36.3	85.5	(58.1-121.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.4	nc	(nc-nc)
Male	5	6.3	79.1	(25.5-184.5)	Female	0	1.2	nc	(nc-nc)
Female	6	3.2	187.4	(68.4-407.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.4	83.0	(33.3-171.0)
Male	2	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.7	nc	(nc-nc)	Female	10	9.6	103.9	(49.7-191.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.9	nc	(nc-nc)	Male	133	137.8	96.5	(80.8-114.4)
Female	3	1.1	nc	(nc-nc)	Female	121	133.6	90.6	(75.1-108.2)
<u>Lung and Bronchus</u>									
Male	24	17.8	135.0	(86.5-200.9)					
Female	22	17.7	124.4	(77.9-188.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.9	nc	(nc-nc)	Male	5	3.0	169.4	(54.6-395.3)
Female	1	1.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	11	13.4	81.8	(40.8-146.4)	Female	1	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	6	5.0	119.4	(43.6-259.8)	<u>Ovary</u>				
Female	4	3.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	15.5	45.2	(18.1-93.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.7	nc	(nc-nc)	Male	45	61.6	73.1	(53.3-97.8)
Female	0	0.4	nc	(nc-nc)	Female	35	43.1	81.2	(56.5-112.9)
<u>Lung and Bronchus</u>									
Male	7	8.9	79.0	(31.7-162.8)					
Female	8	5.9	136.5	(58.8-268.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	8.2	60.6	(19.5-141.5)	Male	1	5.7	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.1	117.5	(42.9-255.8)
Female	21	23.6	88.9	(55.0-135.9)	Female	3	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	4.7	105.4	(34.0-245.9)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	5	9.8	51.2	(16.5-119.6)	<u>Ovary</u>				
Female	9	5.3	168.8	(77.0-320.5)	Female	3	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.4	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	22	30.9	71.2	(44.6-107.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	2	5.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.4	113.7	(36.7-265.4)
Male	4	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	6	5.3	114.1	(41.7-248.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.4	nc	(nc-nc)	Male	77	118.1	65.2	(51.4-81.5)
Female	0	0.6	nc	(nc-nc)	Female	67	73.8	90.8	(70.4-115.3)
<u>Lung and Bronchus</u>									
Male	5	15.5	32.3	(10.4-75.4)					
Female	6	9.9	60.6	(22.1-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	20.7	116.0	(74.3-172.6)	Male	21	11.9	176.3	(109.1-269.4)
Female	9	8.2	110.3	(50.3-209.3)	Female	17	9.4	181.4	(105.6-290.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	8	4.0	201.7	(86.8-397.4)
Female	4	3.0	nc	(nc-nc)	Female	7	3.6	195.1	(78.2-402.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	17	10.7	159.2	(92.7-254.9)
Female	109	79.3	137.5	(112.9-165.9)	Female	7	10.7	65.6	(26.3-135.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	9	8.2	109.6	(50.0-208.1)
<u>Colon / Rectum</u>					Female	5	4.4	113.5	(36.6-264.9)
Male	24	20.2	119.1	(76.3-177.2)	<u>Ovary</u>				
Female	35	22.2	157.4	(109.6-218.9)	Female	6	6.9	87.1	(31.8-189.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.0	nc	(nc-nc)	Male	7	7.0	99.9	(40.0-205.9)
Female	0	1.6	nc	(nc-nc)	Female	11	8.2	133.4	(66.5-238.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.0	479.9	(154.6-1119.8)	Male	98	59.7	164.1	(133.2-199.9)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.7	148.4	(59.5-305.9)
Male	10	10.0	100.0	(47.9-183.9)	Female	1	3.0	nc	(nc-nc)
Female	8	6.6	121.4	(52.3-239.3)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	3.8	131.4	(42.3-306.6)
<u>Leukemia</u>					Female	4	11.4	nc	(nc-nc)
Male	9	7.6	119.0	(54.3-225.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.9	101.3	(37.0-220.5)	Female	20	18.4	108.5	(66.3-167.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.2	nc	(nc-nc)	Male	326	245.7	132.7	(118.7-147.9)
Female	3	2.6	nc	(nc-nc)	Female	326	275.2	118.4	(105.9-132.0)
<u>Lung and Bronchus</u>									
Male	48	36.8	130.5	(96.2-173.0)					
Female	42	42.7	98.3	(70.8-132.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	98.0	(31.6-228.6)	Male	4	3.1	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	16	19.8	80.9	(46.2-131.3)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	5	5.3	93.7	(30.2-218.6)	<u>Ovary</u>				
Female	10	5.2	191.7	(91.8-352.7)	Female	4	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	16	15.5	103.1	(58.9-167.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	6	2.7	221.9	(81.0-482.9)	Female	1	0.7	nc	(nc-nc)
Female	5	1.6	315.5	(101.7-736.2)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.1	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	6	4.4	136.7	(49.9-297.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.7	nc	(nc-nc)	Male	61	63.8	95.7	(73.2-122.9)
Female	0	0.6	nc	(nc-nc)	Female	64	66.1	96.9	(74.6-123.7)
<u>Lung and Bronchus</u>									
Male	8	9.4	85.2	(36.7-167.9)					
Female	5	9.9	50.5	(16.3-117.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	60.1	88.3	(66.1-115.4)	Male	28	38.7	72.3	(48.1-104.6)
Female	31	21.8	142.2	(96.6-201.9)	Female	19	31.9	59.6	(35.9-93.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	12.2	115.2	(62.9-193.3)	Male	11	12.3	89.6	(44.7-160.4)
Female	12	10.3	116.3	(60.0-203.2)	Female	7	10.1	69.6	(27.9-143.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.1	nc	(nc-nc)	Male	33	35.0	94.4	(65.0-132.6)
Female	246	250.4	98.2	(86.4-111.3)	Female	41	31.2	131.4	(94.3-178.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.9	90.2	(38.9-177.8)	Male	32	28.9	110.9	(75.8-156.5)
<u>Colon / Rectum</u>					Female	14	13.3	105.2	(57.5-176.6)
Male	68	66.2	102.7	(79.8-130.2)	<u>Ovary</u>				
Female	72	65.8	109.4	(85.6-137.7)	Female	20	21.7	92.3	(56.4-142.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	15.3	71.7	(35.8-128.4)	Male	27	21.5	125.6	(82.7-182.7)
Female	5	4.3	117.2	(37.8-273.5)	Female	24	22.5	106.5	(68.2-158.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.0	118.9	(43.4-258.8)	Male	148	184.5	80.2	(67.8-94.2)
Female	3	4.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	14.6	116.6	(67.9-186.7)
Male	33	33.8	97.8	(67.3-137.3)	Female	8	8.9	89.8	(38.7-177.0)
Female	24	19.7	121.7	(77.9-181.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	9.5	73.4	(29.4-151.2)
Male	10	8.9	113.0	(54.1-207.8)	<u>Thyroid</u>				
Female	6	2.7	219.7	(80.2-478.2)	Male	17	16.0	106.3	(61.9-170.2)
<u>Leukemia</u>					Female	57	49.2	115.9	(87.8-150.2)
Male	21	25.1	83.6	(51.7-127.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	18	18.7	96.2	(57.0-152.0)	Female	62	55.8	111.2	(85.3-142.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	21.1	80.7	(47.0-129.2)	Male	711	779.2	91.2	(84.7-98.2)
Female	6	7.3	82.7	(30.2-180.0)	Female	888	839.3	105.8	(99.0-113.0)
<u>Lung and Bronchus</u>									
Male	105	104.3	100.6	(82.3-121.8)					
Female	138	112.5	122.7	(103.0-144.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	9.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	6.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	3.6	139.8	(45.0-326.2)
Female	1	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.5	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	12.7	110.2	(60.2-185.0)
Female	0	0.1	nc	(nc-nc)	Female	11	10.7	103.0	(51.3-184.2)
<u>Lung and Bronchus</u>									
Male	4	1.7	nc	(nc-nc)					
Female	1	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	30.7	94.5	(63.2-135.7)	Male	34	18.2	187.3	(129.7-261.7)
Female	9	11.5	78.3	(35.7-148.6)	Female	29	13.9	208.8	(139.8-299.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.2	134.1	(53.7-276.3)	Male	7	5.8	120.4	(48.2-248.1)
Female	6	4.5	133.2	(48.6-289.9)	Female	5	5.1	98.3	(31.7-229.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	13	16.3	79.7	(42.4-136.3)
Female	113	113.5	99.5	(82.0-119.7)	Female	25	15.3	163.5	(105.8-241.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	17	12.7	133.6	(77.8-214.0)
<u>Colon / Rectum</u>					Female	5	6.3	79.0	(25.5-184.3)
Male	31	31.5	98.3	(66.8-139.6)	<u>Ovary</u>				
Female	35	33.2	105.5	(73.5-146.8)	Female	9	9.9	90.8	(41.5-172.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.3	nc	(nc-nc)	Male	8	10.5	75.9	(32.7-149.6)
Female	7	2.2	318.8	(127.7-656.9)	Female	11	11.8	93.2	(46.4-166.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	96	84.8	113.2	(91.7-138.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	7.1	182.5	(97.1-312.2)
Male	14	15.2	92.3	(50.4-154.9)	Female	1	4.5	nc	(nc-nc)
Female	8	9.3	85.7	(36.9-168.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.8	181.2	(58.4-422.9)
Male	2	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
<u>Leukemia</u>					Female	30	18.0	166.6	(112.4-237.8)
Male	15	11.9	126.4	(70.7-208.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	8.9	157.7	(86.2-264.7)	Female	20	25.3	79.1	(48.3-122.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	9.5	nc	(nc-nc)	Male	365	366.6	99.6	(89.6-110.3)
Female	1	3.6	nc	(nc-nc)	Female	402	395.6	101.6	(91.9-112.1)
<u>Lung and Bronchus</u>									
Male	29	52.7	55.0	(36.8-79.0)					
Female	40	58.5	68.4	(48.8-93.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	17	9.6	177.0	(103.0-283.4)	Female	3	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.1	88.0	(37.9-173.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	35	37.1	94.3	(65.7-131.2)
Female	0	0.3	nc	(nc-nc)	Female	43	31.3	137.6	(99.6-185.3)
<u>Lung and Bronchus</u>									
Male	7	5.0	141.4	(56.6-291.3)					
Female	6	4.2	144.4	(52.7-314.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	12.8	132.4	(77.1-212.0)	Male	5	8.3	60.2	(19.4-140.6)
Female	8	4.4	180.0	(77.5-354.6)	Female	3	6.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	5	1.9	257.7	(83.1-601.4)	Female	6	2.0	292.7	(106.9-637.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.4	135.9	(65.0-249.9)
Female	58	52.0	111.5	(84.6-144.1)	Female	8	6.3	127.5	(54.9-251.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.7	nc	(nc-nc)	Male	6	6.1	97.9	(35.7-213.0)
<u>Colon / Rectum</u>					Female	1	2.7	nc	(nc-nc)
Male	22	14.0	157.1	(98.4-237.8)	<u>Ovary</u>				
Female	20	13.1	152.7	(93.2-235.8)	Female	9	4.4	203.4	(92.8-386.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.3	181.7	(66.3-395.4)	Male	6	4.6	130.9	(47.8-284.9)
Female	0	0.9	nc	(nc-nc)	Female	5	4.5	111.5	(35.9-260.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	51	38.8	131.5	(97.9-172.9)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	15	7.1	210.2	(117.6-346.8)	Female	1	1.8	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.4	84.8	(36.5-167.1)
Male	7	5.1	136.1	(54.5-280.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	3.6	197.1	(78.9-406.0)	Female	9	11.6	77.9	(35.5-147.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.5	110.5	(35.6-258.0)	Male	194	165.3	117.4	(101.4-135.1)
Female	1	1.5	nc	(nc-nc)	Female	203	170.9	118.8	(103.0-136.3)
<u>Lung and Bronchus</u>									
Male	20	22.9	87.2	(53.2-134.7)					
Female	34	24.1	141.1	(97.7-197.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	19.1	78.6	(43.9-129.6)	Male	22	12.3	178.2	(111.6-269.8)
Female	11	6.9	159.6	(79.6-285.6)	Female	11	9.6	114.2	(56.9-204.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	7	4.0	175.6	(70.3-361.7)
Female	6	3.1	194.4	(71.0-423.2)	Female	2	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	13	11.1	116.9	(62.2-199.9)
Female	94	77.8	120.8	(97.6-147.8)	Female	8	9.8	81.8	(35.2-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	13	9.5	137.5	(73.2-235.2)
<u>Colon / Rectum</u>					Female	5	4.1	121.1	(39.0-282.6)
Male	15	21.2	70.8	(39.6-116.8)	<u>Ovary</u>				
Female	19	20.6	92.3	(55.5-144.1)	Female	7	6.7	104.6	(41.9-215.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.0	120.0	(43.8-261.1)	Male	11	6.9	158.4	(79.0-283.4)
Female	0	1.3	nc	(nc-nc)	Female	6	7.0	85.6	(31.3-186.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	62	60.9	101.7	(78.0-130.4)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.7	nc	(nc-nc)
Male	7	10.9	64.2	(25.7-132.3)	Female	5	2.8	178.8	(57.6-417.3)
Female	6	6.1	98.1	(35.8-213.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	14.5	76.0	(37.9-136.0)
Male	7	7.8	89.2	(35.7-183.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.6	89.0	(28.7-207.6)	Female	30	17.2	174.0	(117.3-248.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.9	72.1	(23.2-168.3)	Male	242	250.6	96.6	(84.8-109.5)
Female	4	2.3	nc	(nc-nc)	Female	289	260.3	111.0	(98.6-124.6)
<u>Lung and Bronchus</u>									
Male	24	33.8	71.1	(45.5-105.8)					
Female	29	35.9	80.9	(54.2-116.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	8	10.5	76.0	(32.7-149.8)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	10.3	48.4	(15.6-112.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.6	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	28	42.0	66.6	(44.3-96.3)
Female	0	0.3	nc	(nc-nc)	Female	34	32.4	104.8	(72.6-146.5)
<u>Lung and Bronchus</u>									
Male	5	5.9	85.4	(27.5-199.2)					
Female	6	4.1	145.1	(53.0-315.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	13.8	145.2	(88.6-224.2)	Male	11	9.2	119.9	(59.8-214.6)
Female	3	5.0	nc	(nc-nc)	Female	9	7.3	122.7	(56.0-232.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.9	239.7	(96.0-493.8)	Male	5	3.0	169.0	(54.5-394.3)
Female	2	2.4	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.3	120.9	(57.9-222.4)
Female	77	62.2	123.8	(97.7-154.7)	Female	5	7.3	68.9	(22.2-160.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.1	nc	(nc-nc)	Male	8	7.3	110.2	(47.4-217.1)
<u>Colon / Rectum</u>					Female	5	3.2	158.1	(50.9-368.9)
Male	15	15.7	95.6	(53.4-157.6)	<u>Ovary</u>				
Female	14	15.1	93.0	(50.8-156.0)	Female	3	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	53	47.2	112.4	(84.2-147.0)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	10	8.4	119.5	(57.2-219.7)	Female	1	2.0	nc	(nc-nc)
Female	4	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.9	265.4	(85.5-619.4)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	3.9	128.5	(41.4-300.0)
<u>Leukemia</u>					Female	14	11.4	123.0	(67.2-206.4)
Male	6	5.9	102.5	(37.4-223.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.1	nc	(nc-nc)	Female	19	13.9	136.3	(82.0-212.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.2	nc	(nc-nc)	Male	205	188.1	109.0	(94.6-125.0)
Female	4	1.7	nc	(nc-nc)	Female	206	199.9	103.0	(89.5-118.1)
<u>Lung and Bronchus</u>									
Male	15	24.8	60.4	(33.8-99.7)					
Female	23	27.0	85.2	(54.0-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	37.8	76.7	(51.4-110.2)	Male	15	23.5	63.7	(35.6-105.1)
Female	13	15.6	83.2	(44.2-142.2)	Female	11	21.1	52.2	(26.0-93.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	7.5	145.9	(72.7-261.0)	Male	4	7.4	nc	(nc-nc)
Female	5	6.9	72.9	(23.5-170.1)	Female	1	7.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	17	21.4	79.4	(46.2-127.2)
Female	128	162.9	78.6	(65.5-93.4)	Female	18	21.4	84.1	(49.8-132.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.6	124.6	(49.9-256.7)	Male	27	16.7	161.5	(106.4-235.0)
<u>Colon / Rectum</u>					Female	7	8.9	78.9	(31.6-162.6)
Male	41	40.6	101.0	(72.5-137.0)	<u>Ovary</u>				
Female	45	45.9	97.9	(71.4-131.1)	Female	13	14.2	91.4	(48.6-156.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.1	66.0	(24.1-143.7)	Male	14	13.2	106.0	(57.9-177.9)
Female	0	3.0	nc	(nc-nc)	Female	22	16.0	137.1	(85.9-207.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.2	nc	(nc-nc)	Male	95	105.2	90.3	(73.1-110.4)
Female	7	2.8	253.1	(101.4-521.5)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	9.0	77.9	(31.2-160.5)
Male	21	19.8	106.2	(65.7-162.3)	Female	9	6.2	144.2	(65.8-273.7)
Female	10	13.3	75.4	(36.1-138.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	6.0	nc	(nc-nc)
Male	8	5.2	154.2	(66.4-303.8)	<u>Thyroid</u>				
Female	3	1.8	nc	(nc-nc)	Male	1	9.3	nc	(nc-nc)
<u>Leukemia</u>					Female	24	31.1	77.2	(49.4-114.8)
Male	10	15.8	63.2	(30.3-116.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	13.0	61.7	(26.5-121.5)	Female	43	35.3	121.7	(88.1-163.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	12.3	202.9	(131.3-299.6)	Male	464	469.3	98.9	(90.1-108.3)
Female	6	4.9	121.5	(44.4-264.6)	Female	511	564.6	90.5	(82.8-98.7)
<u>Lung and Bronchus</u>									
Male	75	64.2	116.8	(91.8-146.4)					
Female	76	79.7	95.3	(75.1-119.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.1	98.2	(35.9-213.7)	Male	3	3.8	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	26	24.9	104.5	(68.3-153.2)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	6	6.9	87.0	(31.8-189.4)	<u>Ovary</u>				
Female	8	6.9	115.2	(49.6-227.1)	Female	1	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	22	17.1	128.8	(80.7-195.0)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.5	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	4.8	167.7	(72.2-330.4)
Male	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	6	5.2	114.6	(41.9-249.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.1	nc	(nc-nc)	Male	86	76.2	112.8	(90.2-139.3)
Female	0	0.7	nc	(nc-nc)	Female	82	83.8	97.8	(77.8-121.4)
<u>Lung and Bronchus</u>									
Male	13	10.0	130.3	(69.3-222.8)					
Female	11	11.1	98.9	(49.3-177.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.8	93.1	(46.4-166.6)	Male	9	8.5	105.5	(48.1-200.2)
Female	9	4.3	211.4	(96.4-401.2)	Female	11	7.1	155.5	(77.5-278.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.9	172.7	(55.6-403.0)	Male	2	2.7	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.7	91.1	(36.5-187.7)
Female	58	59.6	97.4	(73.9-125.9)	Female	6	6.6	91.3	(33.3-198.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.2	nc	(nc-nc)	Male	8	7.1	112.8	(48.6-222.2)
<u>Colon / Rectum</u>					Female	1	2.9	nc	(nc-nc)
Male	10	14.6	68.6	(32.8-126.1)	<u>Ovary</u>				
Female	12	13.5	88.6	(45.7-154.8)	Female	3	4.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	5	4.5	110.2	(35.5-257.1)
Female	1	0.8	nc	(nc-nc)	Female	7	4.3	162.6	(65.1-335.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	53	42.9	123.7	(92.6-161.7)
Female	3	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.1	nc	(nc-nc)
Male	4	8.1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	0	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	9	4.1	220.3	(100.5-418.3)
<u>Leukemia</u>					Female	16	12.1	132.1	(75.5-214.6)
Male	2	5.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.9	nc	(nc-nc)	Female	12	12.7	94.4	(48.7-165.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.9	nc	(nc-nc)	Male	166	172.5	96.2	(82.2-112.0)
Female	0	1.5	nc	(nc-nc)	Female	179	185.6	96.5	(82.8-111.7)
<u>Lung and Bronchus</u>									
Male	15	21.7	69.1	(38.7-114.0)					
Female	22	23.3	94.3	(59.1-142.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.3	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.7	188.4	(60.7-439.6)
Female	16	17.8	89.8	(51.3-145.8)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	0.8	708.2	(258.6-1541.5)
Male	0	5.1	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.9	129.4	(41.7-302.0)	Female	2	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	14.7	81.6	(42.1-142.5)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.1	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.6	138.7	(44.7-323.6)
Male	2	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	45	59.5	75.7	(55.2-101.3)
Female	0	0.4	nc	(nc-nc)	Female	60	54.2	110.7	(84.4-142.5)
<u>Lung and Bronchus</u>									
Male	4	7.7	nc	(nc-nc)					
Female	8	6.5	122.2	(52.6-240.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	22.0	104.7	(66.3-157.1)	Male	13	14.2	91.7	(48.8-156.8)
Female	8	8.2	97.3	(41.9-191.8)	Female	10	11.2	89.5	(42.9-164.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.3	162.3	(65.0-334.4)	Male	4	4.6	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	7	12.7	55.2	(22.1-113.8)
Female	89	92.8	95.9	(77.0-118.0)	Female	11	11.4	96.8	(48.3-173.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	13	10.8	120.3	(64.0-205.8)
<u>Colon / Rectum</u>					Female	6	4.8	124.7	(45.5-271.5)
Male	26	23.9	108.8	(71.1-159.4)	<u>Ovary</u>				
Female	34	23.2	146.6	(101.5-204.8)	Female	8	7.9	101.4	(43.7-199.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.8	nc	(nc-nc)	Male	1	7.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	7	8.3	84.8	(34.0-174.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	69	73.5	93.8	(73.0-118.8)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.3	nc	(nc-nc)
Male	8	12.8	62.6	(27.0-123.3)	Female	5	3.1	159.1	(51.3-371.4)
Female	10	7.4	134.5	(64.4-247.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.9	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	6	5.8	103.8	(37.9-226.0)
<u>Leukemia</u>					Female	28	16.5	170.1	(113.0-245.9)
Male	6	8.9	67.4	(24.6-146.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	6.5	nc	(nc-nc)	Female	22	20.8	105.6	(66.1-159.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	7.7	65.0	(20.9-151.6)	Male	251	291.6	86.1	(75.8-97.4)
Female	2	2.7	nc	(nc-nc)	Female	309	308.1	100.3	(89.4-112.1)
<u>Lung and Bronchus</u>									
Male	28	40.4	69.3	(46.1-100.2)					
Female	34	44.8	75.8	(52.5-106.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.8	115.8	(66.1-188.0)	Male	17	8.8	193.1	(112.4-309.2)
Female	7	5.4	130.7	(52.3-269.2)	Female	14	7.1	195.8	(107.0-328.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	60	60.9	98.5	(75.1-126.8)	Female	12	7.4	161.1	(83.2-281.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.8	nc	(nc-nc)	Male	6	6.8	88.8	(32.4-193.3)
<u>Colon / Rectum</u>					Female	7	3.2	220.5	(88.3-454.3)
Male	15	14.7	102.3	(57.2-168.8)	<u>Ovary</u>				
Female	15	15.1	99.5	(55.7-164.2)	Female	6	5.2	115.1	(42.0-250.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.7	nc	(nc-nc)	Male	5	5.0	99.5	(32.1-232.1)
Female	1	1.1	nc	(nc-nc)	Female	6	5.3	112.8	(41.2-245.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	0.8	nc	(nc-nc)	Male	43	46.9	91.8	(66.4-123.6)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.4	nc	(nc-nc)
Male	11	7.8	140.6	(70.1-251.6)	Female	1	2.0	nc	(nc-nc)
Female	6	4.9	123.3	(45.0-268.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.3	385.4	(124.2-899.4)
Male	4	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.7	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	10.1	69.4	(27.8-143.0)
Male	4	5.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.1	nc	(nc-nc)	Female	17	14.2	119.8	(69.8-191.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	5.1	253.2	(134.7-433.1)	Male	193	182.3	105.9	(91.5-121.9)
Female	0	1.8	nc	(nc-nc)	Female	218	200.6	108.7	(94.7-124.1)
<u>Lung and Bronchus</u>									
Male	22	25.6	86.0	(53.9-130.2)					
Female	33	29.6	111.6	(76.8-156.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	10	9.2	108.7	(52.0-199.9)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.0	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	3	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	1.7	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	33	29.7	111.0	(76.4-155.9)
Female	0	0.2	nc	(nc-nc)	Female	33	29.1	113.5	(78.1-159.5)
<u>Lung and Bronchus</u>									
Male	6	3.9	154.5	(56.4-336.3)					
Female	5	4.1	120.8	(38.9-281.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.8	95.4	(55.6-152.8)	Male	17	11.3	150.4	(87.6-240.8)
Female	9	6.7	133.6	(61.0-253.6)	Female	8	8.6	93.4	(40.2-183.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	10.1	128.4	(68.3-219.6)
Female	88	72.2	121.9	(97.7-150.1)	Female	8	9.3	86.4	(37.2-170.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	9	8.6	104.6	(47.7-198.5)
<u>Colon / Rectum</u>					Female	7	3.9	180.7	(72.4-372.4)
Male	17	19.3	87.9	(51.2-140.7)	<u>Ovary</u>				
Female	16	19.3	82.7	(47.2-134.3)	Female	5	6.2	80.6	(26.0-188.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.7	214.5	(102.7-394.5)	Male	7	6.4	108.6	(43.5-223.8)
Female	3	1.3	nc	(nc-nc)	Female	6	6.9	87.5	(31.9-190.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	66	58.0	113.8	(88.0-144.8)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.3	nc	(nc-nc)
Male	6	10.0	59.9	(21.9-130.4)	Female	6	2.6	228.7	(83.5-497.8)
Female	6	5.7	104.5	(38.1-227.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.8	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	14	11.5	121.8	(66.5-204.4)
Male	4	7.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.1	97.7	(31.5-228.0)	Female	14	16.5	84.8	(46.3-142.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.3	78.9	(25.4-184.1)	Male	239	232.0	103.0	(90.4-117.0)
Female	4	2.2	nc	(nc-nc)	Female	251	242.6	103.5	(91.1-117.1)
<u>Lung and Bronchus</u>									
Male	22	32.3	68.1	(42.7-103.1)					
Female	26	35.2	73.9	(48.3-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	14.3	83.9	(43.3-146.5)	Male	16	9.1	175.4	(100.2-284.9)
Female	6	5.6	106.6	(38.9-232.0)	Female	10	7.5	133.5	(63.9-245.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	7	8.1	86.1	(34.5-177.4)
Female	51	61.8	82.5	(61.5-108.5)	Female	8	7.8	102.8	(44.3-202.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.0	nc	(nc-nc)	Male	5	6.7	74.1	(23.9-173.0)
<u>Colon / Rectum</u>					Female	4	3.2	nc	(nc-nc)
Male	14	15.4	90.7	(49.5-152.1)	<u>Ovary</u>				
Female	9	16.6	54.1	(24.7-102.7)	Female	2	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.6	nc	(nc-nc)	Male	12	5.1	234.3	(120.9-409.3)
Female	4	1.1	nc	(nc-nc)	Female	9	5.7	157.0	(71.6-298.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	41	43.0	95.3	(68.3-129.2)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.5	144.0	(46.4-336.1)
Male	7	7.8	89.3	(35.8-184.1)	Female	1	2.3	nc	(nc-nc)
Female	2	4.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.8	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	3.5	142.6	(45.9-332.7)
<u>Leukemia</u>					Female	15	10.9	137.0	(76.6-226.0)
Male	9	5.8	156.3	(71.3-296.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.5	nc	(nc-nc)	Female	15	13.3	113.2	(63.3-186.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.1	nc	(nc-nc)	Male	183	182.9	100.1	(86.1-115.7)
Female	1	1.8	nc	(nc-nc)	Female	203	207.0	98.1	(85.0-112.5)
<u>Lung and Bronchus</u>									
Male	26	25.6	101.6	(66.3-148.8)					
Female	27	29.3	92.2	(60.7-134.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.5	87.0	(41.7-160.1)	Male	8	7.7	103.8	(44.7-204.5)
Female	5	3.9	127.0	(40.9-296.4)	Female	4	6.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.9	72.7	(23.4-169.8)
Female	49	50.6	96.9	(71.7-128.1)	Female	5	5.8	85.6	(27.6-199.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	7	6.3	111.5	(44.7-229.6)
<u>Colon / Rectum</u>					Female	4	2.6	nc	(nc-nc)
Male	10	13.0	76.9	(36.8-141.5)	<u>Ovary</u>				
Female	9	11.8	76.5	(34.9-145.2)	Female	5	4.2	117.7	(37.9-274.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.2	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	35	42.2	82.9	(57.7-115.3)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.9	nc	(nc-nc)
Male	5	7.2	69.5	(22.4-162.1)	Female	0	1.6	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.2	156.4	(50.4-364.9)
<u>Leukemia</u>					Female	15	9.3	160.9	(90.0-265.4)
Male	3	4.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.3	nc	(nc-nc)	Female	13	11.7	111.6	(59.4-190.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.5	nc	(nc-nc)	Male	139	160.5	86.6	(72.8-102.2)
Female	3	1.4	nc	(nc-nc)	Female	161	161.2	99.9	(85.1-116.6)
<u>Lung and Bronchus</u>									
Male	14	21.6	64.8	(35.4-108.8)					
Female	19	21.4	88.8	(53.4-138.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.2	84.9	(34.0-175.0)	Male	6	5.5	108.7	(39.7-236.6)
Female	4	2.2	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.0	141.0	(56.5-290.6)
Female	28	28.2	99.5	(66.1-143.7)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	9	9.0	99.6	(45.5-189.1)	<u>Ovary</u>				
Female	4	6.7	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	34	28.5	119.2	(82.6-166.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.7	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.6	90.1	(29.0-210.2)
Male	4	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.0	nc	(nc-nc)	Female	3	6.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.0	nc	(nc-nc)	Male	100	112.9	88.6	(72.1-107.7)
Female	1	0.8	nc	(nc-nc)	Female	81	91.3	88.7	(70.4-110.3)
<u>Lung and Bronchus</u>									
Male	7	15.0	46.6	(18.7-96.0)					
Female	11	12.3	89.5	(44.6-160.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.8	nc	(nc-nc)	Male	5	2.0	246.4	(79.4-575.0)
Female	1	1.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	11	12.5	87.9	(43.8-157.3)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	10	11.3	88.6	(42.4-162.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.4	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	45	42.2	106.7	(77.8-142.8)
Female	1	0.3	nc	(nc-nc)	Female	36	40.3	89.2	(62.5-123.5)
<u>Lung and Bronchus</u>									
Male	9	5.5	164.1	(74.9-311.6)					
Female	3	5.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	49.4	109.4	(82.2-142.7)	Male	9	34.6	26.0	(11.9-49.4)
Female	16	19.7	81.1	(46.3-131.7)	Female	9	32.8	27.4	(12.5-52.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	12.8	70.4	(32.1-133.7)	Male	11	10.7	103.2	(51.5-184.7)
Female	8	11.3	71.1	(30.6-140.1)	Female	18	9.3	193.4	(114.5-305.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	21	31.3	67.1	(41.5-102.6)
Female	175	250.4	69.9	(59.9-81.1)	Female	35	29.9	117.2	(81.6-163.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	18	9.9	182.0	(107.8-287.7)	Male	31	26.6	116.4	(79.1-165.2)
<u>Colon / Rectum</u>					Female	12	12.8	93.5	(48.2-163.3)
Male	57	57.1	99.8	(75.6-129.3)	<u>Ovary</u>				
Female	44	61.3	71.8	(52.2-96.4)	Female	10	21.4	46.7	(22.3-85.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	13.4	59.6	(25.7-117.5)	Male	19	18.3	104.0	(62.6-162.3)
Female	9	3.9	230.4	(105.1-437.4)	Female	14	20.3	68.8	(37.6-115.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	6.1	nc	(nc-nc)	Male	217	165.2	131.4	(114.5-150.1)
Female	7	5.3	132.4	(53.1-272.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	12.4	168.7	(104.4-257.9)
Male	24	31.2	77.0	(49.3-114.6)	Female	16	8.3	192.6	(110.0-312.8)
Female	24	19.3	124.6	(79.8-185.5)	<u>Testis</u>				
<u>Larynx</u>					Male	9	12.0	74.8	(34.1-142.0)
Male	10	7.9	127.0	(60.8-233.5)	<u>Thyroid</u>				
Female	3	2.6	nc	(nc-nc)	Male	14	16.4	85.6	(46.8-143.7)
<u>Leukemia</u>					Female	62	56.7	109.4	(83.9-140.2)
Male	16	23.4	68.3	(39.0-110.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	18.8	101.3	(60.9-158.1)	Female	49	54.5	89.9	(66.5-118.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	37	19.0	195.0	(137.3-268.8)	Male	723	694.7	104.1	(96.6-111.9)
Female	14	6.8	205.1	(112.0-344.2)	Female	716	823.3	87.0	(80.7-93.6)
<u>Lung and Bronchus</u>									
Male	92	89.4	102.9	(83.0-126.2)					
Female	97	103.4	93.8	(76.1-114.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	9.1	165.3	(92.4-272.6)	Male	6	5.3	113.1	(41.3-246.1)
Female	1	2.6	nc	(nc-nc)	Female	6	3.5	172.3	(62.9-374.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	5	1.1	438.5	(141.3-1023.3)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	26	28.9	89.9	(58.7-131.7)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	6	9.0	67.0	(24.5-145.9)	<u>Ovary</u>				
Female	6	7.2	83.7	(30.6-182.1)	Female	2	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.3	222.1	(71.6-518.4)	Male	3	3.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	20	27.1	73.8	(45.1-114.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.1	nc	(nc-nc)
Male	5	4.5	111.5	(35.9-260.2)	Female	4	1.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.9	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	5	6.8	73.9	(23.8-172.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	107	110.0	97.2	(79.7-117.5)
Female	1	0.9	nc	(nc-nc)	Female	97	96.8	100.2	(81.3-122.2)
<u>Lung and Bronchus</u>									
Male	19	16.1	118.2	(71.2-184.7)					
Female	18	14.3	125.9	(74.6-199.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.0	100.4	(51.8-175.4)	Male	14	7.8	178.4	(97.4-299.3)
Female	5	4.8	104.9	(33.8-244.8)	Female	7	6.4	109.0	(43.7-224.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	7.0	nc	(nc-nc)
Female	43	52.5	81.9	(59.3-110.3)	Female	4	6.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.7	nc	(nc-nc)	Male	8	6.0	132.3	(57.0-260.8)
<u>Colon / Rectum</u>					Female	3	2.8	nc	(nc-nc)
Male	11	13.2	83.6	(41.7-149.6)	<u>Ovary</u>				
Female	7	13.6	51.6	(20.7-106.2)	Female	6	4.6	131.9	(48.2-287.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.2	154.8	(49.9-361.4)	Male	1	4.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	29	40.0	72.4	(48.5-104.0)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.9	nc	(nc-nc)
Male	5	7.0	71.4	(23.0-166.6)	Female	0	1.8	nc	(nc-nc)
Female	6	4.2	141.6	(51.7-308.1)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	9.3	53.5	(17.3-124.9)
Male	12	4.9	244.5	(126.2-427.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.7	135.5	(43.7-316.1)	Female	13	12.0	108.7	(57.8-185.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.5	nc	(nc-nc)	Male	144	160.5	89.7	(75.6-105.6)
Female	0	1.6	nc	(nc-nc)	Female	148	176.4	83.9	(70.9-98.5)
<u>Lung and Bronchus</u>									
Male	17	21.8	77.8	(45.3-124.7)					
Female	19	25.7	73.9	(44.4-115.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	11.3	150.1	(87.4-240.3)	Male	8	6.0	133.4	(57.5-262.9)
Female	2	3.9	nc	(nc-nc)	Female	6	4.1	146.4	(53.4-318.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	110.9	(40.5-241.3)
Female	38	33.5	113.4	(80.3-155.7)	Female	4	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	15	10.6	141.6	(79.2-233.6)	<u>Ovary</u>				
Female	16	10.9	146.3	(83.6-237.7)	Female	6	3.0	198.1	(72.3-431.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.5	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	4.1	122.0	(39.3-284.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	24	27.6	86.9	(55.7-129.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.5	nc	(nc-nc)
Male	5	4.6	108.3	(34.9-252.7)	Female	0	1.5	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.3	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.8	nc	(nc-nc)	Female	7	7.7	90.6	(36.3-186.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	110	122.1	90.1	(74.1-108.6)
Female	0	1.2	nc	(nc-nc)	Female	127	122.7	103.5	(86.3-123.2)
<u>Lung and Bronchus</u>									
Male	12	18.5	65.0	(33.5-113.5)					
Female	18	19.3	93.5	(55.4-147.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	60	46.9	127.9	(97.6-164.7)	Male	22	29.5	74.6	(46.7-112.9)
Female	28	15.2	183.7	(122.0-265.5)	Female	17	21.8	78.0	(45.4-124.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	8.7	57.3	(18.5-133.6)	Male	11	9.5	116.2	(57.9-208.0)
Female	8	6.9	115.2	(49.6-227.1)	Female	4	7.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	24	26.5	90.5	(57.9-134.6)
Female	176	173.7	101.3	(86.9-117.5)	Female	24	21.6	110.9	(71.0-165.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	6.0	149.2	(68.1-283.3)	Male	22	21.5	102.2	(64.0-154.8)
<u>Colon / Rectum</u>					Female	10	9.2	109.1	(52.2-200.7)
Male	43	50.8	84.7	(61.3-114.1)	<u>Ovary</u>				
Female	33	46.0	71.8	(49.4-100.8)	Female	30	14.9	200.8	(135.5-286.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	11.7	111.0	(59.0-189.8)	Male	13	16.5	78.7	(41.9-134.6)
Female	3	2.9	nc	(nc-nc)	Female	17	15.6	109.1	(63.5-174.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.5	nc	(nc-nc)	Male	136	137.6	98.8	(82.9-116.9)
Female	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	11.2	115.6	(61.5-197.7)
Male	30	25.3	118.6	(80.0-169.3)	Female	2	6.2	nc	(nc-nc)
Female	14	13.7	102.5	(56.0-172.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	6.3	nc	(nc-nc)
Male	9	6.8	133.3	(60.8-253.0)	<u>Thyroid</u>				
Female	0	1.9	nc	(nc-nc)	Male	12	11.6	103.4	(53.3-180.5)
<u>Leukemia</u>					Female	23	33.5	68.7	(43.6-103.2)
Male	17	18.8	90.6	(52.7-145.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	12.7	94.6	(48.8-165.3)	Female	43	38.1	113.0	(81.8-152.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	15.8	44.4	(17.8-91.5)	Male	559	590.8	94.6	(86.9-102.8)
Female	3	5.0	nc	(nc-nc)	Female	597	581.1	102.7	(94.7-111.3)
<u>Lung and Bronchus</u>									
Male	79	81.4	97.0	(76.8-120.9)					
Female	90	79.4	113.3	(91.1-139.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;